Click to read
the new issue

April 2014
Go back
  • NICE final "yes" to Xarelto

    May 24, 2012

    In final guidance, NICE has recommended the use of Bayer HealthCare's Xarelto (rivaroxaban) as an option for the prevention of stroke and systemic embolism in people with atrial fibrillation (AF).

    Full story

  • Good news from NICE for Xarelto, Xgeva

    April 03, 2012

    Following the receipt of further evidence from Bayer HealthCare of Xarelto's clinical and cost-effectiveness, NICE has issued final draft guidance recommending it an option for the prevention of stroke and systemic embolism in people with atrial fibrillation.

    Full story

  • B-I cuts Pradaxa's price by 13%

    March 29, 2012

    Boehringer Ingelheim has announced that it is reducing the cost of its oral anticoagulant Pradaxa (dabigatran etexilate) by 13%, to £2.20 per day, from April 1.

    Full story

  • NICE seeks more info on Bayer's Xarelto

    January 10, 2012

    NICE has published preliminary recommendations asking Bayer for more information on its oral anticoagulant Xarelto (rivaroxaban).

    Full story

  • New approvals for Bayer's Xarelto

    December 20, 2011

    Following new European Commission approvals, Bayer's Xarelto is now available for use in the UK for two new indications.

    Full story

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. Next page

JobSearch


Head-to-Head Video

 

Website Search


Search News Search Magazine